Nayak Chitra S, Ray Somshukla, Thombre Anil, Jain Mahim
Department of Dermatology, Topiwala National Medical College and BYL Nair Charitable Hospital, Mumbai Central, Mumbai, India.
Indian J Dermatol Venereol Leprol. 2014 Jul-Aug;80(4):296-9. doi: 10.4103/0378-6323.136831.
The introduction of dexamethasone-cyclophosphamide pulse (DCP) therapy for the pemphigus group of disorders by Pasricha has revolutionized the therapy for pemphigus. There are very few studies regarding factors affecting duration of phase I of the DCP.
Our purpose was to study the relationship between various factors and duration of the phase I.
A retrospective study of 98 patients of pemphigus on Dexamethasone Pulse therapy was conducted. Patients were classified according to duration of Phase 1 as those with phase I less than 6 months and those more than 6 months and analyzed for variable factors affecting duration of phase I.
Disease severity in pemphigus significantly prolonged the duration of phase I of DCP. Longer duration was also observed in patients on concurrent oral steroid therapy (both statistically significant).
The findings from our study help us to address patient expectations and apprehensions regarding duration of therapy. A detailed understanding of the various patient and disease related factors responsible for affecting Phase I duration will help in better management of the patient, and the disease.
帕斯里查引入的地塞米松-环磷酰胺冲击（DCP）疗法彻底改变了天疱疮疾病组的治疗方法。关于影响DCP第一阶段持续时间的因素的研究非常少。
我们的目的是研究各种因素与第一阶段持续时间之间的关系。
对98例接受地塞米松冲击治疗的天疱疮患者进行了回顾性研究。根据第一阶段的持续时间，将患者分为第一阶段少于6个月和多于6个月的两组，并分析影响第一阶段持续时间的可变因素。
天疱疮的疾病严重程度显著延长了DCP第一阶段的持续时间。同时接受口服类固醇治疗的患者也观察到较长的持续时间（两者均具有统计学意义）。
我们研究的结果有助于我们解决患者对治疗持续时间的期望和担忧。详细了解影响第一阶段持续时间的各种患者和疾病相关因素将有助于更好地管理患者和疾病。
